Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.83B | 2.76B | 2.50B | 2.08B | 1.77B | 1.49B | Gross Profit |
1.93B | 1.92B | 1.85B | 1.51B | 1.31B | 1.14B | EBIT |
-1.03B | -1.05B | -215.01M | -577.54M | -835.47M | -558.35M | EBITDA |
-848.74M | -788.73M | 41.88M | -386.74M | -617.73M | -632.86M | Net Income Common Stockholders |
-1.02B | -1.03B | -204.15M | -623.51M | -595.63M | -848.53M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
786.17M | 1.04B | 777.64M | 632.06M | 1.03B | 1.84B | Total Assets |
5.71B | 5.93B | 6.47B | 6.23B | 6.68B | 4.93B | Total Debt |
2.52B | 2.75B | 2.55B | 2.45B | 2.36B | 1.46B | Net Debt |
2.17B | 2.15B | 1.95B | 2.20B | 2.05B | -27.11M | Total Liabilities |
3.31B | 3.53B | 3.33B | 3.18B | 3.30B | 2.10B | Stockholders Equity |
2.40B | 2.40B | 3.15B | 3.04B | 3.39B | 2.82B |
Cash Flow | Free Cash Flow | ||||
194.14M | 74.55M | 31.93M | -438.02M | -238.00M | 72.13M | Operating Cash Flow |
323.66M | 210.54M | 156.12M | -223.56M | -102.24M | 136.48M | Investing Cash Flow |
-305.15M | -442.15M | 49.68M | 74.07M | -1.08B | -702.04M | Financing Cash Flow |
-21.30M | 231.87M | 159.77M | 76.48M | 8.47M | 1.88B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $10.28B | 113.68 | 2.67% | 2.80% | 3.31% | ― | |
67 Neutral | $22.97B | ― | -18.66% | ― | 51.50% | 53.23% | |
59 Neutral | $10.05B | ― | -36.89% | ― | 11.57% | -315.25% | |
57 Neutral | $6.11B | ― | -4584.47% | ― | 28.20% | 13.87% | |
55 Neutral | $953.63M | ― | -8.57% | ― | 10.10% | 8.79% | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
52 Neutral | $14.29B | ― | -23.82% | ― | -3.47% | 25.55% |
On June 12, 2025, Exact Sciences Corporation held its annual meeting where shareholders approved the 2025 Omnibus Long-Term Incentive Plan and an amendment to the 2010 Employee Stock Purchase Plan. Additionally, the shareholders elected seven directors, ratified the appointment of PricewaterhouseCoopers as the company’s independent auditor for 2025, and approved executive compensation. However, a proposal for a director election resignation governance policy was not approved.
The most recent analyst rating on (EXAS) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
On April 29, 2025, Exact Sciences Corporation appointed Leslie Trigg as a Class II member of its Board of Directors, following the resignation of Kathleen Sebelius. Ms. Trigg, with over 25 years of experience in the healthcare and medical device industries, is expected to bring valuable leadership and investor relations skills to the company, potentially strengthening its market position.